Lack of Documented Rationale for Declined Psychotropic Medication Recommendations
Summary
The deficiency involves the facility’s failure to ensure that prescribers documented individualized clinical rationales when declining consultant pharmacist recommendations for gradual dose reductions or dose changes of psychotropic medications, and failure to sign and date those recommendations. For one resident with unspecified dementia, anxiety, and depression who had severe cognitive impairment and was receiving aripiprazole, the pharmacist recommended a dose reduction of 5 mg daily. The recommendation form was marked as denied but contained no documented rationale explaining why the physician declined the gradual dose reduction, and the electronic health record also lacked any physician explanation. The Regional Clinical Support Nurse confirmed that no physician rationale could be provided and acknowledged that such documentation should have been present. For another resident with insomnia and unspecified Alzheimer’s disease, who had severe cognitive deficit and was receiving trazodone 50 mg at bedtime, the pharmacist recommended changing the dose to 25 mg at bedtime PRN for 14 days with reevaluation of need. The physician declined this recommendation, but the recommendation form did not include any justification for the declination. Psychiatry and behavioral health progress notes from the same period documented that the resident reported eating and sleeping well and denied sleep issues, and staff reported the resident was stable and functioning at baseline. Despite this, there was no documented physician rationale on the pharmacy recommendation form explaining the decision to continue the existing trazodone regimen. For a third resident with unspecified dementia with psychotic disturbance, severe cognitive deficit, and receiving both antipsychotic and antianxiety medications, the pharmacist recommended a dose reduction of quetiapine from 100 mg twice daily to 50 mg in the morning and 100 mg at bedtime. The physician declined, noting only that the resident was on hospice, without further individualized justification. Additionally, this recommendation form lacked the physician’s signature and date. A separate pharmacist recommendation to reduce alprazolam from 0.25 mg three times daily to twice daily was also declined without a documented rationale, and that form likewise lacked the physician’s signature and date. Behavior tracking reports from the same period showed the resident continued to experience anxiety-related behaviors. The facility’s own policy required that prescribers either accept pharmacist suggestions or reject them with an explanation, which was not followed in these cases.
Penalty
Resources
Below are regulatory guidelines relevant to this citation:
Trusted data from CMS and state health departments
Every citation, penalty and Plan of Correction is sourced from public CMS records (latest release August 26, 2026) and official state health department websites — never guesswork.
In your survey window? See what surveyors are citing.
The Survey-Prep Report maps your facility's risk from 12 months of CMS and state citation data — what's being cited around you and what to check first. $129 one-time.